Bostwick to Market Metabolon's Prostate Cancer Risk Stratification Test | GenomeWeb

NEW YORK (GenomeWeb News) – Metabolon and Bostwick Laboratories today announced an exclusive marketing agreement covering Metabolon's Prostarix test for stratifying prostate cancer risk.

Under the agreement, Bostwick — a full-service laboratory specializing in uropathology, particularly the diagnosis of urological cancers — will market Prostarix for the initial determination of which men may be candidates for prostate biopsy, as well as the determination of which men who have had prior negative biopsies may need repeat biopsies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.